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Chronic venous disease (CVD) encompasses a spectrum of clinical presentations, with severity increasing from telangiectasia to varicose veins (VVs), oedema, skin changes and venous ulceration. While presentations differ, a constant outcome remains, namely, an impact on patients' health-related quality of life (HRQoL), defined by the World Health Organisation as "individuals' perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns". 1 This concept is enshrined in clinical guidelines, both to reflect effectiveness of intervention from a patient perspective and to assess cost-effectiveness using quality adjusted life years (QALYs) 2 estimated from HRQoL score improvements. 3 Multiple HRQoL tools exist. Generic tools, such as the EuroQoL-5D, contain multidimensional questions assessing biopsychosocial functioning together with overall perceptions of health. While applicable to various diseases, their broad nature precludes identification of condition-specific attributes. Conversely, disease-specific tools may be employed to explore issues unique to named conditions; commonly employed CVD-specific tools include the Aberdeen Varicose Vein Questionnaire (AVVQ), Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ) and VEnous INsufficiency Epidemiological And Economic Study-QoL/Symptoms (VEINESQoL/Sym). 4 Criteria established in an evaluation of patientreported outcome measures (PROMs) 5 have been used to validate CVD-specific tools, which largely support the use of the commoner tools listed above. However, a review reported scarcity of validation studies, with only the AVVQ, CIVIQ and VEINES-QoL/ Sym considered thoroughly validated. This is despite the AVVQ and CIVIQ having only ever been validated by their creators, with further linguistic validation only. 4 This leads to some concerns. Firstly, validation studies published solely by the creators lead to questions regarding bias. Secondly, even if no partiality exists, the validation studies are limited to local populations; these tools have been applied to international populations despite questionable generalisability. Finally, the paucity of validation studies for other existing tools raises the question of whether tools have been created sequentially despite unsubstantiated needs.
Despite these potential issues, studies have established that these commonly used tools correlate with clinical severity assessed using the Venous Clinical Severity Score and CEAP classification. 6, 7 However, with nine items in the AVVQ focusing on symptoms and signs, correlation with clinical severity is not surprising. While this relationship is less uncertain for the CIVIQ with a single question on symptoms, the VEINES-QoL/Sym, with nine of the 26 items focusing on symptoms, may face the same pitfalls as the AVVQ.
Furthermore, given the multidimensionality of HRQoL, unidimensional correlation with severity is clearly insufficient. Tools should holistically evaluate the biopsychosocial issues experienced by patients. A good balance of questions has to be achieved, preferably weighted to best reflect each domain's impact, but these weightages differ markedly for current tools. The AVVQ focuses greatly on the physical effects of VVs, while the CIVIQ emphasises more on the psychosocial domains in C 0-4 disease. The VEINES-QoL/Sym shows further generalisation, covering broad CVD related domains, but this generalisability causes insensitivity to symptomology changes in VVs. 3 There may be no agreement to which weightage works best as the importance of each domain can vary between patients. There may be a role for individualisation of HRQoL scores, with importance of each domain determined independently for individual patients, or for preferential use of HRQoL tools for specific outcomes.
Furthermore, tool usage must be acceptable to all users. In the busy lives of clinicians and patients, tools should ideally be completed within each clinical encounter. Therein lies a trade-off -tools have to be sufficiently extensive to ensure complete assessment, yet short enough to be completed in a time-effective fashion. Current tools are considerably lengthy, ranging from the 13-item AVVQ, 14-or 20-item CIVIQ, and finally the 26-item VEINES-QoL/Sym. This is further extended by complexity, with question phrasing and additional tasks potentially confounding the lay patient. With the removal of the time-consuming manikin diagram in the AVVQ leading to seemingly valid scores, 8 and questionnaire fatigue a significant problem in clinical trials, 3 should current tools be further simplified to improve acceptability to patients?
Finally, HRQoL scores can help make clinical decisions and determine intervention effectiveness. This utility was recognised by the United Kingdom's Department of Health which consolidated efforts to collect and publish PROMs for common procedures, 9 providing excellent data for quality improvement and research purposes. Ultimately though, tools have to be optimised for clinical application to prevent score collection from becoming a mere academic exercise. To do so, a minimal clinically important difference (MCID), defined as the smallest score change perceived beneficial by patients, should be determined. To the authors' knowledge, the MCIDs of CVD-specific tools have yet to be calculated, with clinical studies often estimating these values with poor results 10 and reflected in the NICE guidelines which defaulted to an estimate of MCIDs citing insufficient evidence. 2 With no specific thresholds, it is impossible to objectively quantify whether interventions achieve more than just technical and clinical success. As for economic success, while it has been suggested that HRQoL scores, instead of QALYs, may be used to determine cost-effectiveness, 3 an economic evaluation of minimally invasive techniques failed to create an economic model citing a lack of HRQoL evidence. 11 Further work is needed to determine the magnitude of impact represented by each point difference and in so doing, allow a dollar-value to be allocated to HRQoL improvements.
Does an optimal CVD-specific HRQoL tool exist? Clinicians should be aware of the limitations of CVDspecific tools; application of an inappropriate tool is akin to not using a tool at all. Even when appropriately used, few CVD-specific tools cover the entire CVD spectrum -the VEINES-QoL/Sym is currently considered the best candidate due to its aforementioned generalisability. 3 Before HRQoL scores are definitively used in determining the clinical-and cost-effectiveness of CVD treatment, current tools must undergo indepth evaluation to further establish validity and determine the interpretability of scores to prevent an inadvertent decline into non-evidence-based medicine. These shortcomings must be addressed and, perhaps, the development of a new, improved tool may be considered.
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